Author: Editor

Doreen M. Agnese, MD of The OSU Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute and/or Yale University School of Medicine discusses Surgical and Radiation Treatment Updates to Management of Breast Cancer, Including SABCS UpdatesLink To Event -https://web.cvent.com/event/1e5680ef-4f00-4f94-aae2-4e43c3d17eac/websitePage:645d57e4-75eb-4769-b2c0-f201a0bfc6ceLink To Dr. Agnese’s Bio -https://cancer.osu.edu/find-a-doctor/search-physician-directory/doreen-m-agnese Latest Clinical Trial – https://clinicaltrials.gov/ct2/show/NCT01901094 I’m a surgical oncologist, clinical geneticist, and researcher who treats breast cancer patients. I specialize in treating high-risk breast cancer patients as a surgeon.   I advise patients as a geneticist on risk assessments based on family background, genetic testing and preventive screening choices, and treatments. My research focuses…

Enrique M. Ocio, MD, Ph.D. of the Marqués de Valdecilla University Hospital discusses ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) – Updated Efficacy and Safety.Link To Study -https://ashpublications.org/blood/article/136/Supplement%201/9/470073/ANCHOR-OP-104-Melflufen-Plus-Dexamethasone-dex-andContext:RRMM patients also develop resistance to conventional therapy, emphasizing the need for new treatments and new mechanisms of action (MOA). A first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells is melphalan flufenamide (melflufen).In the phase 2 HORIZON study (OP-106; overall response rate [ORR], 29 percent; median progression-free…

Matthew Smith, MD, Professor of Medicine of Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center Speaks about the ASCO GU 2021 Abstracts Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial and Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.Link To The Abstract 239 – https://meetinglibrary.asco.org/record/195160/abstractLink To The Abstract 240 – https://meetinglibrary.asco.org/record/194935/abstract   Abstract 240 – Analysis of the effect of a placebo (PBO) crossover on the overall survival…

Matthew Smith, MD, Professor of Medicine of Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center discusses the U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information.Link To the Study -https://bayer2019tf.q4web.com/news/news-details/2021/U.S.-FDA-Approves-Addition-of-Overall-Survival-and-Other-Secondary-Endpoint-Data-to-NUBEQA-darolutamide-Prescribing-Information/default.aspxPhase III results showed that NUBEQA care resulted in a 31 percent reduction in death risk, with a statistically significant increase in overall survival (OS) relative to placebo (HR=0.69, 95 percent CI 0.53-0.88; p=0.003), giving men with non-metastatic castration-resistant prostate cancer (nmCRPC) the chance to prolong their lives.For men living with nmCRPC, time to pain…

Dr. Irene Ghobrial and Dr. Karen Winkfield give us guidance on a basic action we can all take to help in the fight against multiple myeloma

Dr. Irene Ghobrial and Dr. Karen Winkfield discuss the ground-breaking study on the disease that will aid in developing new parameters for prevention and treatment

Dr. Irene Ghobrial and Dr. Karen Winkfield discuss the markers surrounding the disease and those people most at risk for developing it

Dr. Irene Ghobrial and Dr. Karen Winkfield describe the symptoms of the disease and how their research study is aiding in prevention

Dr. Irene Ghobrial and Dr. Karen Winkfield talk about the necessity for research to stem the incidence of multiple myeloma

Grzegorz S. Nowakowski, MD from the Mayo Clinic speaks about the Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.Link To Study -https://ascopubs.org/doi/full/10.1200/JCO.20.01375Intent —In untreated diffuse large B-cell lymphoma (DLBCL), lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) showed promising activity, particularly in the activated B-cell-like (ABC) subtype. A randomized phase II study comparing R2CHOP versus R-CHOP in untreated DLBCL was the Eastern Cooperative Oncology Group (ECOG)-ACRIN trial E1412.METHODS AND PATIENTSQualified and randomly allocated 1:1 to R2CHOP versus R-CHOP for six…

Conor E. Steuer, MD from the Winship Cancer Institute of Emory University in Atlanta discusses Patients with Lung Cancer Reduce Smoking Rate After Enrollment in Phase III Clinical Trial.Link To Article -https://www.eurekalert.org/pub_releases/2021-02/iaft-pwl013021.php(DENVER—February 1, 2021, 10:00 a.m. EST) According to research published today in the Journal of Thoracic Oncology, the first systematic, prospective study of smoking habits in patients with non-small cell lung cancer (NSCLC) who were involved in a phase III early-stage trial showed that there was a high rate of smoking reduction and cessation following entry into the study. The JTO is the International Association for the Study of…

William Gradishar, MD, FASCO, FACP from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University speaks about Updates to the Systemic Treatment of Metastatic Breast Cancer, Including SABCS Updates.Link to NCCN 2021 Flier -https://custom.cvent.com/A534AF7FE15948CAB67ABDABC062DF76/files/42384271dfff470b80f3c1476934d325.pdfWilliam J. Gradishar, MD, is Professor of Breast Oncology at Betsy Bramsen, Professor of Medicine, and Chief of the Hematology and Medical Oncology Division at Northwestern University’s Feinberg School of Medicine. Dr. Gradishar is also the Deputy Director for the Robert H. Lurie Comprehensive Cancer Center’s Clinical Network, where he also acts as Director of the Maggie Daley Center for Women’s Cancer Treatment. In addition, he…

Co-hosts Charu Aggarwal and Jack West are joined by Dr. Toni Choueiri to discuss the role of twitter for education, mentorship and a platform for sharing credible information.Visit https://BeaconMedIC.com for more media and information.Subscribe to audio podcast at http://BTJBeacon.libsyn.com/rss/audio

Erica L. Mayer, MD, MPH of the Dana-Farber Cancer Institute discusses Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.SummaryContextIn hormone-receptor-positive, HER2-negative, metastatic breast cancer, the addition of palbociclib to endocrine therapy increases progression-free survival. The aim of the PALLAS trial was to investigate whether the addition of 2 years of palbociclib to adjuvant endocrine therapy enhances invasive disease-free survival in patients with hormone-receptor-positive, HER2-negative, early-stage breast cancer over endocrine therapy alone.MethodologyPALLAS is an ongoing multicentre, open-label, randomized, phase 3 trial that has recruited patients with histologically confirmed hormone-receptor-positive,…

Omar Nadeem, MD from Dana-Farber Cancer Institute speaks about HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations.Context:RRMM pts are a very ill group due to signs of illness, comorbidities, medication side effects, and age-related fragility (Chim et al. Leukemia. 2018;32:252). Adverse events (AEs) that impair their quality of life and decrease medication compliance are also encountered by Pts; hematologic AEs are frequent. Inpatient facilities are also required for AE management and are a significant cost driver, with costs increasing per AE episode (highest for hematologic AEs; Felber et…

Erminia Massarelli, MD Ph.D. from the City of Hope speaks about Lung Cancer: Her Experience, Research, And The Current Treatment Landscape.Link To Dr. Massarelli’s Biography -https://www.cityofhope.org/people/massarelli-erminia

Clayton S. Lau, MD of the City of Hope speaks about Prostate Cancer: His Experience, Research, And The Current Treatment Landscape.Link to Dr. Lau’s Biography -https://www.cityofhope.org/people/lau-clayton

Joanne Mortimer, MD from the City of Hope speaks about Breast Cancer: Her Experience, Research, And The Current Treatment LandscapeLink to Dr. Mortimer’s Biography -https://www.cityofhope.org/people/mortimer-joanne

Geoffrey M. Lowman, Ph.D. from Thermo Fisher Scientific discusses Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing.For more information on -OncomineTM TCR Beta-LR Assay -https://www.thermofisher.com/order/catalog/product/A35386?us&en#/A35386?us&enInstractContext:As a risk factor for autoimmune disorders and immune-related adverse effects (IRAEs) during immunotherapy, polymorphism within the human T-cell receptor beta variable (TRBV) gene has been suggested. The repetitive nature of the T-cell receptor beta (TCRB) locus has hindered previous attempts to test TRBV polymorphism through whole genome sequencing. To allow TRBV haplotype analysis from peripheral blood, we present a novel long-amplicon TCRB repertoire sequencing approach.Methodology:For the sequencing of TCRB…

Uri Ben-David, Ph.D. Assistant Professor, Department of Human Molecular Genetics and Biochemistry at the Tel Aviv University speaks about the AARC 2020 – Abstract NG02: Genomic evolution of cancer models: Perils and opportunities.InstractCancer precision medicine is based on the premise that the drug response is correlated with the unique genomic features of a human tumor. Therefore, its vulnerabilities could be predicted by analyzing the genomic features of a tumor, and appropriate treatment could then be tailored. To achieve this goal, a detailed “dependence map” needs to be established that would allow each tumor’s “Achilles heel” to be predicted based on…

CPI-613 (Devimistat) + Cytarabine + Mitoxantrone in Acute Myeloid Leukemia (AML) FDA Fast Track Designation CPI-613 (Devimistat) Demonstrates Positive Outcomes in Relapsed/Refractory Acute AML This is a clinical trial that is designed for patients with acute myeloid leukemia (AML). They have already received prior therapy and either relapsed or refractory aml to the prior therapy. So, it’s what we call salvage therapy and the design of the CPI-613 (Devimistat) study is that of the patient. It’s a phase 3 randomized multicenter clinical trial. CPI-613 (Devimistat) + Cytarabine + Mitoxantrone in Acute Myeloid Leukemia Study Design It’s a large study and…

Josep Tabernero, MD, PhD, Head of Medical Oncology at Vall d’Hebron Barcelona Hospital, and Director, Vall d’Hebron Institute of Oncology (VHIO) discusses Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study (Phase3).Context:Metastatic gastroesophageal cancer (GC/GEJC) is a poorly prognosed and aggressive disease with a median overall survival (mOS) of around 1 year. Although new therapies have appeared, given the heterogeneity of the disease, the need for a deeper understanding of biology and patient profiling is important. Previously, in strongly pretreated metastatic GC/GEJC patients with a 31 percent…

Tito R. Mendoza, Ph.D., MS, MEd from The University of Texas MD Anderson Cancer Center discusses Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.InstractIntroducing:Immunotherapies have revolutionized the treatment of multiple cancers, but their symptomatic toxicity is little understood. By questioning the patients themselves, the diagnosis of these symptoms is better done. Such studies, however, are subjective and, like bonafide science evidence, can face challenges. Demonstrating the validity of symptom evaluation methods, particularly through the elimination of measurement errors, if these tools are widely adopted, has the potential to improve patient care. To that end,…

Michael A. Pulsipher, MD from the Cancer and Blood Disease Institute, Children’s Hospital Los Angeles discusses Continued Role for Radiation in the Conditioning Regimen for Children With ALL.Link To Full Article:https://ascopubs.org/doi/full/10.1200/JCO.20.03261The outcomes of the 413 randomly selected patients showed an unequivocal increase in survival using the TBI method. A startling 28 percent (86 percent v 58 percent; P < .0001) of event-free survival (EFS) was higher at 2 years. For a population where the advantage was not apparent and did not work, the authors looked very hard. CR1 patients had an EFS gain of 24 percent (91 percent v 67…

Jonathan Shamash MBChB, MD, MRCP of Barts and The London NHS Trust speaks about The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG).InstractContextFor the Anglian Network, the germ cell supranetwork multidisciplinary team (SMDT) serves a population of 7.5 million.MethodologyWe analyzed and classified 10 years of SMDT discussion into five domains ((1) overall result, (2) untreated disease and salvage therapy chemotherapy regimens, (3) radiology, (4) pathology, and (5) complex cases) to determine the effects of SMDT.OutcomesThere were a total of 2892 new cases reviewed. In…

Stephen M. Ansell, MD, Ph.D. from the Mayo Clinic, Rochester speaks about the review: Checkpoint BLOCKade in Lymphoma.Link To Paper -https://ascopubs.org/doi/abs/10.1200/JCO.20.01522InstractAlong with advances in genomic research, the clinical development of successful cancer immunotherapies has led to the discovery of tumor environmental characteristics that predict susceptibility to immune control point blockade therapy (CBT). The remarkable efficacy of CBT in various lymphoma subtypes, including classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma, has been demonstrated in early-phase clinical trial findings. Conversely, for follicular lymphoma and diffuse large B-cell lymphoma, CBT has been relatively disappointing. Together with significant scientific findings, these clinical studies…

Vered Stearns, MD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins discusses Taking an individualized approach to preventing and treating breast cancer, specifically metastatic Triple Negative Breast Cancer in African American Women.Link To The Article:https://www.v.org/2020/vered-stearns-m-d/Vered Stearns, M.D., and Roisin Connolly, M.D., of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, obtained one such grant. Their team uses an individualized approach, specifically metastatic Triple Negative Breast Cancer, to prevent and treat breast cancer (TNBC). Compared to white women, African American women are more likely to get TNBC and more likely to get the most violent form and to…

Jean-Jacques Kiladjian, M.D., Ph.D. from Saint-Louis Hospital and Paris Diderot University in France speaks about the ASH abstract – 481 Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension.Introducing:Life-long care is required in patients with polycythemia vera (PV) in order to avoid thromboembolic events and minimize the risk of progression. By selectively targeting the malignant clone, ropeginterferon alpha-2b (BESREMi®; hereafter ropeg) will eventually alter the natural history of PV. In the PROUD-PV/CONTINUATION-PV trials, long-term ropeg therapy was contrasted with normal cytoreductive therapy for thromboembolic and other adverse reactions, as well as…

DUBLIN – January 27, 2021 – Mallinckrodt plc, a global biopharmaceutical company, announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft versus host disease (cGvHD) in adults. The approval was based on an open-label study conducted in patients with steroid-resistant or intolerant cGvHD after allogeneic hematopoietic stem cell transplantation at three institutions in Japan. The efficacy rate following evaluation of response and changes in steroid dose 24-weeks after ECP initiation was 66.7 percent (8/12 patients), the primary endpoint of the study. Adverse events were observed in…

Danelle James, M.D., M.A.S. of Pharmacyclics, an AbbVie company discusses IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström’s Macroglobulinemia (WM).Today, AbbVie reported that the U.S. The update of the IMBRUVICA® (ibrutinib) Prescription Details has been approved by the Food and Drug Administration (FDA) to provide efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström’s macroglobulinemia (WM) based on the final review of Phase 3 iNNOVATE trial. IMBRUVICA is currently available for patients with many forms of blood cancer, as well as chronic graft-versus-host disease, and was first approved in 2013. On…

Gypsyamber D’Souza, Ph.D. from Johns Hopkins, Bloomberg School of Public Health speaks about Timing, number, and type of sexual partners associated with the risk of oropharyngeal cancerInstractContextCase-control research from the early 2000s found that oropharyngeal cancer associated with human papillomavirus (HPV-OPC) is a different entity linked to the number of oral sex partners. We examined novel risk factors (sexual debut habits, exposure intensity, and relationship dynamics) and serological markers on HPV-OPC odds using current data.MethodologyFrom 2013 to 2018, HPV-OPC patients and frequency-matched controls were enrolled in a multicenter trial. A behavioral survey was conducted by respondents. Using a chi-square test…

Guillermo Garcia-Manero, MD from The University of Texas MD Anderson Cancer Center speaks about ASH 2020 Abstract – 1230 Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)Clinically Relevant AbstractIntroducing:The standard of care for the treatment of MDS and CMML is developed with hypomethylating agents (HMAs) or DNA methyltransferase inhibitors (DNMTi) such as decitabine or azacitidine. Because of the rapid degradation of cytidine deaminase (CDA) in the gut and liver, the oral bioavailability of these agents has been reduced, requiring intravenous infusion or subcutaneous injections daily for 5-7 days per…

Andreana N. Holowatyj, Ph.D., MS Assistant Professor of Medicine and Cancer Biology from Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center discusses Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age at Disease Onset. InstractSignificance:The incidence of appendiceal cancer (AC) is growing with unknown etiologies, especially among individuals younger than 50 years of age (early onset of AC). In patients with early-onset AC, the unique spectrum of somatic cancer gene variations is largely undetermined.Target:To classify the frequency of somatic variations and genomic trends in early-onset (<50 years of age) vs late-onset (<50 years of age) AC patients.Plan,…

Sophie G Kellaway and Prof Constanze Bonifer from the Institute of Cancer and Genomic Sciences, University of Birmingham speaks about the Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories.InstractImportance:  In patients with early-onset AC, the unique spectrum of somatic cancer gene variations is largely undetermined.Objective: Plan, environment, and participants: This cohort study included individuals diagnosed with pathologically confirmed AC aged 18 years and older. The International Clinicogenomic Data Sharing Consortium American Association for Cancer Research Project Genomics Proof Neoplasia Knowledge Exchange reported cases with clinical-grade targeted sequencing data from January 1, 2011, to December 31, 2019. (GENIE). From May to…

Kohei Shitara, MD, Chief, Department of Gastrointestinal Oncology of the National Cancer Center Hospital East, Kashiwa discusses The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.Context:It is unclear if prior therapy with ramucirumab (RAM) or RAM plus paclitaxel (PAC), the standard second-line therapy for metastatic gastric or gastroesophageal junction cancer (mGC/GEJC), can affect the outcomes of third-line chemotherapy in this patient population (pt) (pop). FTD/TPI demonstrated a survival advantage vs. placebo (PBO) in pts with mGC/GEJC that had received = 2 previous chemotherapy regimens in the phase 3 TAGS trial. In order to…

Nathan Connell, MD, MPH, FACP of Brigham and Women’s Hospital, Harvard Medical School speaks about ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.Context:A prevalent hereditary bleeding disorder is von Willebrand disease (VWD). In management options provided to patients, substantial variability occurs.Target:The aim of these evidence-based recommendations from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) is to help patients, physicians, and health care practitioners in their VWD management decisions.Methodology:The multidisciplinary guideline panel was founded by ASH, ISTH,…

Teresa Klinowska, Ph.D. Global Product Leader, Late Stage Oncology at AstraZeneca discussed the SABCS 20 abstract – SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancerPrincipal abstracts include:New results from the Phase II DESTINY-Breast01 trial reinforcing the long-lasting efficacy of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in HER2-positive metastatic breast cancer after two or more previous anti-HER2 regimensNew results from the SERENA-1 Phase I trial, which demonstrated good efficacy and safety in HR-positive, HER2-negative advanced breast cancer, for the next generation oral selective oestrogen receptor degrader (SERD), AZD9833 as monotherapy, and in…

Michele Ghidini, MD, Ph.D., Medical Oncologist, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan, Italy speaks about Body weight loss (BWL) as a prognostic/predictive factor in previously treated patients (pts) with metastatic gastric or gastroesophageal junction cancer (mGC/GEJC): Post-hoc analyses of the phase III tags trialContext:Nutritional status is closely related to cancer mortality, and in curative, first- and second-line settings in mGC/GEJC, BWL has been shown to be prognostic for survival. Trifluridine/tipiracil (FTD/TPI) demonstrated clinical advantage against placebo (PBO) and manageable protection in pts with mGC/GEJC that had obtained = 2 previous chemotherapy regimens in the phase III TAGS trial.…

Aung Naing, MD, FACP of MD Anderson discusses the Phase 2 study of pembrolizumab in patients with advanced rare cancers.InstractContext:There is a poor prognosis for patients with advanced rare cancers with few treatment options. We aimed to test pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients with advanced, rare cancers as immunotherapy is successful across multiple types of cancer.Methodology:In this open-label, phase 2 study, nine tumor-specific cohorts and a 10th cohort for other unusual histologies were included in patients with advanced rare cancers whose tumors had progressed to standard therapies, if appropriate, during the previous 6 months. Pembrolizumab 200…

Omar M. Abdel-Rahman Abdelsalam, MBBCh, MSc, MD, Assistant Professor of Medical Oncology from the University of Alberta discusses the New Research in JNCCN Highlights Dangerous Disparities for Life-Saving Cancer Screening.PLYMOUTH MEETING, Pa., Jan. 13, 2021 /PRNewswire/ — New research in the January 2021 issue of the JNCCN-National Comprehensive Cancer Network Journal shows that more than a third of qualifying individuals skip timely colorectal cancer screening tests and at least a fifth tend to miss timely breast and cervical cancer screening tests. The research comes from the University of Alberta, Faculty of Medicine, and Dentistry in Alberta, Canada, with findings from…

Afsaneh Barzi, MD, medical oncologist at the City of Hope discusses the ASCO GI 2020 Discussion- Disparities in Access to Screening and Variation of Targets in Different Groups.https://meetings.asco.org/gi/friday-program

Afsaneh Barzi, MD, medical oncologist at the City of Hope discusses the ASCO GI 2020 Abstract – Health-related quality of life and time from diagnosis among young adult colorectal cancer survivors.Context:The incidence of colorectal cancer (CRC) is growing among patients under 50 years of age. The quality of life of survivors in this population is not well represented. In CRC survivors = 50 years old, who were 6-18 months or 19-36 months from initial diagnosis or relapse, we compared health-related quality of life (HRQoL).Methodology:In conjunction with a national association for young CRC survivors, a cross-sectional online survey was conducted. To…

We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. Access to the full agenda can…

We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. Access to the full agenda can…

We are excited to be able to offer videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum, presented by the Global Resource for Advancing Cancer Education (GRACE). This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung…

We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials. Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program. Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University…

We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials. Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program. Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University…

Helene Rundqvist of the Karolinska Institutet speaks about Cytotoxic T-cells mediate exercise-induced reductions in tumor growth.An abstract:Exercise has a large spectrum of structural impacts. Repeated exertion decreases malignant tumor growth in animal models, and exercise can improve outcomes for cancer patients clinically. Like the cellular agents involved, the etiology of the impact of exercise on tumor development is unknown. We show here that exercise-induced reduction of tumor growth in mice is dependent on CD8+ T cells, and that metabolites produced in skeletal muscle and excreted in plasma in both mice and humans at high levels during exercise enhance the effector…

Larysa Sanchez, MD from Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute speaks about the ASH 2020 Abstract – 3242 Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)REFERENCE:The most frequently used triplet combination regimens in patients (pts) with RRMM in the US are PIs paired with a Rd backbone. The hallmark research supporting the effectiveness of these regimens were primarily in pts without prior exposure to lenalidomide (R).1,2 Real-world studies…